Affordable Access

Development of a novel monoclonal antibody-based competitive ELISA for antibody detection against bovine leukemia virus.

Authors
  • Wang, Jing
  • Sun, Chao
  • Hu, Zhe
  • Wang, Fangzhou
  • Chang, Jitao
  • Gao, Ming
  • Ye, Dandan
  • Jia, Qi
  • Zou, Hui
  • Willems, Luc
  • Jiang, Zhigang
  • Yin, Xin
Publication Date
Apr 13, 2024
Source
ORBi
Keywords
Language
English
License
Unknown
External links

Abstract

peer reviewed / Infection with bovine leukemia virus (BLV) leads to enzootic bovine leukosis, the most prevalent neoplastic disease in cattle. Due to the lack of commercially available vaccines, reliable eradication of the disease can be achieved through the testing and elimination of BLV antibody-positive animals. In this study, we developed a novel competitive ELISA (cELISA) to detect antibodies against BLV capsid protein p24. Recombinant p24 protein expressed by Escherichia coli, in combination with the monoclonal antibody 2G11 exhibiting exceptional performance, was used for the establishment of the cELISA. Receiver-operating characteristic curve analysis showed that the sensitivity and specificity of the assay were 98.85 % and 98.13 %, respectively. Furthermore, the established cELISA was specific for detecting BLV-specific antibodies, without cross-reactivity to antisera for six other bovine viruses. Significantly, experimental infection of cattle and sheep with BLV revealed that the cELISA accurately monitors seroconversion. In a performance evaluation, the established cELISA displayed a high agreement with Western blotting and the commercial BLV gp51 cELISA kit in the detection of 242 clinical samples, respectively. In conclusion, the novel p24 cELISA exhibited the potential to be a reliable and efficient diagnostic tool for BLV serological detection with a broad application prospect.

Report this publication

Statistics

Seen <100 times